sglt2 vs glp 1 vs dpp4 Effect of dual inhibition of and on tacrolimus‐induced diabetes mellitus and nephrotoxicity in a rat model - Ko - 2022 - American Journal of Transplantation Insights into the Roles of

Medication use, infection risk, imaging, and physical exam findings matter more than labs alone

Electrolyte Solutions: (Generic Pedialyte) Essential for combating the systemic dehydration commonly caused by GLP-1 medications

Methods The current study involves the fusion of a native or mutant GLP-1 (30 residues) with an HSA-binding DARPin (123 residues) via a rigid helical linker (15 residues) to create fusion proteins (168 residues) resistant to DPP-IV and, or trypsin with extended half-lives using structural modeling, which are subsequently characterized using MD simulation and molecular docking analyses

Petrizzo, G

Here is a summary of the data for Alabama: Medicaid spending on GLP-1s (past 12 months): $43,100,970 Medicaid spending on GLP-1s (YoY change): +107% Medicaid spending on GLP-1s per enrollee (past 12 months): $55 Total Medicaid enrollment: 787,325 Wegovy coverage (obesity-indicated): Yes Zepbound coverage (obesity-indicated): No Saxenda coverage (obesity-indicated): No Ozempic coverage (Type 2 diabetes-indicated): Yes Mounjaro coverage (Type 2 diabetes-indicated): Yes Rybelsus coverage (Type 2 diabetes-indicated): Yes For reference, here are the statistics for the entire United States: Medicaid spending on GLP-1s (past 12 months): $3,452,602,033 Medicaid spending on GLP-1s (YoY change): +142% Medicaid spending on GLP-1s per enrollee (past 12 months): $48 Total Medicaid enrollment: 72,429,055 Wegovy coverage (obesity-indicated): 34 states Zepbound coverage (obesity-indicated): 16 states Saxenda coverage (obesity-indicated): 19 states Ozempic coverage (Type 2 diabetes-indicated): 51 states* Mounjaro coverage (Type 2 diabetes-indicated): 46 states* Rybelsus coverage (Type 2 diabetes-indicated): 46 states *Including District of Columbia Methodology The data used in this study comes from IRIS by Real Chemistrya proprietary market intelligence platform fueled by billions of data points, including medical, hospital, and pharmacy claims covering more than 300 million U.S

Prager et al., 2015